SESN receives CRL for Vicineum in NMIBC: https://finance.yahoo.com/news/sesen-bio-receives-complete-response-184000117.html The FDA has determined that it cannot approve the BLA for Vicineum in its present form and has provided recommendations specific to additional clinical/statistical data and analyses in addition to Chemistry, Manufacturing and Controls (CMC) issues pertaining to a recent pre-approval inspection and product quality. Other than those things, the BLA is in pretty good shape, LOL.